Skip to main content

Advertisement

SpringerLink
Log in

Oncologists tap the microbiome in bid to improve immunotherapy outcomes

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

A pioneering Merck & Co.-funded study is set to explore the ability of the microbiome to boost immuno-oncology therapy outcomes, and other companies are quickly gearing up to enter this clinical space.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Oncologists tap the microbiome in bid to improve immunotherapy outcomes. Nat Rev Drug Discov 17, 153–155 (2018). https://doi.org/10.1038/nrd.2018.19

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.19

  • Springer Nature Limited

This article is cited by

Search

Navigation